BrightInsight Named 2019 Google Cloud Technology Partner of the Year for the Healthcare Industry for Second Year in Row Built on Google Cloud Platform, the BrightInsight Platform supports and optimizes regulated drugs, devices and software through integrated data and...
Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI) Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics...
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors – FDA Grants Priority Review and sets PDUFA Date of August 13,...
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock WALTHAM, Mass.–(BUSINESS WIRE)–Feb. 19, 2020– Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key...
Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease NYX-458 is currently under evaluation in a Phase 2 study in patients with mild cognitive impairment associated...
Aptinyx Announces Pricing of Public Offering of Common Stock EVANSTON, Ill., Jan. 10, 2020 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system...
Recent Comments